E-Medicare Pharma
Online Medicine Pharmacy
0.00$
Selpacta (Selpercatinib) 40 mg is a medication used in the treatment of certain types of advanced or metastatic cancers, particularly non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC), and other solid tumors. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the activity of specific abnormal proteins that promote cancer cell growth. Selpacta 40 mg offers a targeted therapy option for patients with cancers harboring specific genetic alterations, helping to slow tumor progression and improve survival outcomes.
1. Indications:
Selpacta (Selpercatinib) 40 mg is indicated for the treatment of:
2. Pharmacology:
Selpacta (Selpercatinib) 40 mg exerts its pharmacological effects by selectively inhibiting the activity of rearranged during transfection (RET) tyrosine kinase receptors, which are involved in cancer cell proliferation and survival. By targeting aberrant RET signaling pathways, Selpacta inhibits tumor growth and metastasis, particularly in cancers harboring RET gene alterations.
3. Dosage and Administration:
The recommended dosage of Selpacta (Selpercatinib) 40 mg may vary depending on the type of cancer being treated, patient characteristics, and individual tumor molecular profile. Typically, the prescribed dose is 120 mg taken orally twice daily, with or without food. Treatment should continue until disease progression, unacceptable toxicity, or other treatment discontinuation criteria are met. Dose adjustments or discontinuation may be necessary based on individual patient response and tolerability.
4. Interaction:
Selpacta (Selpercatinib) 40 mg may interact with other medications, including:
Patients should inform their healthcare provider about all medications they are taking, including prescription, over-the-counter, and herbal products, to avoid potential interactions.
5. Side Effects:
Common side effects associated with Selpacta (Selpercatinib) 40 mg may include:
Patients should report any persistent or severe side effects to their healthcare provider for further evaluation and management.
6. Precautions and Warnings:
Before using Selpacta (Selpercatinib) 40 mg, patients should be aware of the following precautions:
7. Overdose Effects:
In case of overdose with Selpacta (Selpercatinib) 40 mg, supportive care should be initiated, and symptomatic treatment may be administered as necessary. There is no specific antidote for Selpercatinib overdose, and patients should seek immediate medical attention if overdose is suspected.
Generic Name: | Selpercatinib |
---|---|
Theraputic Category: | Anti-Cancer |
Pack Size: | 30’s |
Previous Product
Next Product
Begin your journey to better health . Join now to unlock exclusive tips and insights sent straight to your inbox, empowering you to embrace a healthier lifestyle each and every day.
Online Medicine Pharmacy
+8801929123476 emedicarepharma@gmail.com
65, mymansingh High-way, Dhaka-1230, Bangladesh